flutamide has been researched along with Body Weight in 69 studies
Flutamide: An antiandrogen with about the same potency as cyproterone in rodent and canine species.
Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine the effect of flutamide on vaginal histology, and to ascertain whether flutamide regulates body weight gain in the ovariectomized rat model." | 7.73 | Influence of ovariectomy and flutamide treatment on vaginal tissue and body weight. ( Gumusalan, Y; Ozbag, D; Ozdemir, N; Saruhan, BG, 2005) |
| "Flutamide, when administered subcutaneously to female rats at doses of 3, 10, or 30 mg/kg/day during late pregnancy (gestational days 16-21), significantly and dose-dependently decreased anogenital distance (AGD) of the male offspring in each dose group compared to controls." | 7.72 | Effects of flutamide on sex maturation and behavior of offspring born to female rats treated during late pregnancy. ( Fujii, Y; Furuyama, Y; Goto, K; Koizumi, K; Saika, O; Saito, K; Suzuki, H; Suzuki, K; Takaori, H, 2004) |
| " Immediately after the completion of resuscitation, as well as 24 and 48 h thereafter, the animals received either vehicle, 10 mg/kg body weight (BW) flutamide or 25 mg/kg BW flutamide subcutaneously." | 7.69 | Flutamide: a novel agent for restoring the depressed cell-mediated immunity following soft-tissue trauma and hemorrhagic shock. ( Angele, MK; Ayala, A; Chaudry, IH; Cioffi, WG; Wichmann, MW, 1997) |
| "Fifty NMRI mice (7-8 weeks old) were randomly divided into five groups, including non-PCOS, PCOS and PCOS groups treated with clomiphene citrate (18 mg/kg body weight for 2 days), metformin (50 mg/100 g body weight for 30 days) and flutamide (10 mg/kg body weight injection for 15 days)." | 4.12 | Metformin, clomiphene citrate and flutamide effects on oocyte ultrastructure status and quality in PCOS mouse model. ( Esmaeilnezhad, S; Ghasemian, F, 2022) |
| " Rats received an intraperitoneal (ip) injection of 200 mg/kg body weight of N-diethylnitrosamine (DEN) and fed a diet containing 0, 0." | 3.78 | Mechanistic study on liver tumor promoting effects of flutamide in rats. ( Hayashi, H; Inokuma, H; Mitsumori, K; Shibutani, M; Shimamoto, K; Suzuki, K; Tawfeeq, MM, 2012) |
| "To determine the effect of flutamide on vaginal histology, and to ascertain whether flutamide regulates body weight gain in the ovariectomized rat model." | 3.73 | Influence of ovariectomy and flutamide treatment on vaginal tissue and body weight. ( Gumusalan, Y; Ozbag, D; Ozdemir, N; Saruhan, BG, 2005) |
| " Androgen receptors could not be immunohistochemically identified in the pancreas at 20 weeks, and dietary treatment with flutamide, an androgen receptor antagonist, did not influence the chronic pancreatitis." | 3.72 | Estradiol alleviates acinar cell apoptosis and chronic pancreatitis in male Wistar Bonn/Kobori rats. ( Arakawa, T; Hashimoto, T; Itoh, M; Joh, T; Kuno, A; Nakamura, S; Nakazawa, T; Nomura, T; Ohara, H; Sano, H; Sogawa, M; Takahashi, S; Yamada, T, 2003) |
| "Flutamide, when administered subcutaneously to female rats at doses of 3, 10, or 30 mg/kg/day during late pregnancy (gestational days 16-21), significantly and dose-dependently decreased anogenital distance (AGD) of the male offspring in each dose group compared to controls." | 3.72 | Effects of flutamide on sex maturation and behavior of offspring born to female rats treated during late pregnancy. ( Fujii, Y; Furuyama, Y; Goto, K; Koizumi, K; Saika, O; Saito, K; Suzuki, H; Suzuki, K; Takaori, H, 2004) |
| "Groups of five male and five female Wistar rats were treated by gavage with 0, 1, 10, and 100 mg flutamide/kg body weight for at least 28 days to investigate whether proposed enhancements to the current subacute rodent OECD test guideline no." | 3.71 | Feasibility and potential gains of enhancing the subacute rat study protocol (OECD test guideline no. 407) by additional parameters selected to determine endocrine modulation. A pre-validation study to determine endocrine-mediated effects of the antiandro ( Andrews, P; Becka, M; Eiben, R; Freyberger, A; Hartmann, E; Loof, I; Schmidt, U; Temerowski, M, 2001) |
| " Immediately after the completion of resuscitation, as well as 24 and 48 h thereafter, the animals received either vehicle, 10 mg/kg body weight (BW) flutamide or 25 mg/kg BW flutamide subcutaneously." | 3.69 | Flutamide: a novel agent for restoring the depressed cell-mediated immunity following soft-tissue trauma and hemorrhagic shock. ( Angele, MK; Ayala, A; Chaudry, IH; Cioffi, WG; Wichmann, MW, 1997) |
| " The present study was undertaken to determine whether androgen blockade with flutamide (15 mg/kg body weight orally daily) would influence bone turnover or bone composition (1) in female rats with intact ovaries and (2) in rats made estrogen-deficient with the luteinizing hormone releasing hormone (LHRH) agonist, buserelin (25 micrograms/kg body weight per day SC)." | 3.68 | Flutamide-mediated androgen blockade evokes osteopenia in the female rat. ( Gold, E; Goulding, A, 1993) |
| "Forty-nine men with prostate cancer were treated with ADT before beginning radical therapy for 6 months." | 2.71 | The influence of androgen deprivation therapy on metabolism in patients with prostate cancer. ( Anraku, T; Ishizaki, F; Nishiyama, T; Shimura, H; Takahashi, K, 2005) |
| "Flutamide treatment in LET females reversed elevated T levels and restored ovarian expression of Cyp17a1 (critical for androgen synthesis) to normal levels." | 1.48 | Antiandrogen Treatment Ameliorates Reproductive and Metabolic Phenotypes in the Letrozole-Induced Mouse Model of PCOS. ( Malik, S; Mellon, PL; Ryan, GE, 2018) |
| "Co-treatment with flutamide (low or high) resulted in oocyte atresia." | 1.43 | Does anti-androgen, flutamide cancel out the in vivo effects of the androgen, dihydrotestosterone on sexual development in juvenile Murray rainbowfish (Melanotaenia fluviatilis)? ( Bhatia, H; Kumar, A, 2016) |
| "Flutamide treatment did not affect disinhibited behavior in testosterone-treated rats." | 1.36 | The aromatase inhibitor 1,4,6-androstatriene-3,17-dione (ATD) reduces disinhibitory behavior in intact adult male rats treated with a high dose of testosterone. ( Svensson, AI, 2010) |
| "Acyline treatment reduced the number of hemorrhagic cysts and the number of Sertoli-like filled cords within ArKO ovaries." | 1.36 | The lack of estrogen and excess luteinizing hormone are responsible for the female ArKO mouse phenotype. ( Drummond, AE; Findlay, JK; Jones, ME; Liew, SH, 2010) |
| " The aim was to assess whether the joint effects of vinclozolin, flutamide, and procymidone can be predicted based on dose-response data of the individual chemicals." | 1.34 | Dysgenesis and histological changes of genitals and perturbations of gene expression in male rats after in utero exposure to antiandrogen mixtures. ( Axelstad, M; Christiansen, S; Dalgaard, M; Hass, U; Kiersgaard, MK; Kortenkamp, A; Metzdorff, SB; Scholze, M; Vinggaard, AM, 2007) |
| "Flutamide treatment significantly attenuated the development of hypertension in female rats (systolic blood pressure: treated, 134." | 1.32 | Abolition of end-organ damage by antiandrogen treatment in female hypertensive transgenic rats. ( Andreev, D; Bader, M; Baltatu, O; Cayla, C; Iliescu, R, 2003) |
| "Roles of androgens in testicular tumor development have been investigated in our previous studies using double-mutant mice lacking inhibins and carrying the null testicular feminization (tfm) mutation of the androgen receptor." | 1.32 | Sexually dimorphic roles of steroid hormone receptor signaling in gonadal tumorigenesis. ( Agno, JE; Burns, KH; Chen, L; Haupt, B; Korach, KS; Matzuk, MM; Ogbonna, SC, 2003) |
| " For the current studies, male rats were dosed for 15 days via oral gavage and euthanized on the morning of test day 15." | 1.31 | Evaluation of a 15-day screening assay using intact male rats for identifying antiandrogens. ( Frame, SR; Ladics, GS; O'Connor, JC, 2002) |
| "Body weights were unaffected whereas liver weights were increased in prochloraz-treated animals." | 1.31 | Antiandrogenic effects in vitro and in vivo of the fungicide prochloraz. ( Andersen, HR; Dalgaard, M; Jørgensen, EB; Nellemann, C; Vinggaard, AM, 2002) |
| " To determine the antiandrogenic potential of fenitrothion in vivo, 7-week-old castrated Sprague-Dawley rats were dosed once a day for 7 days with testosterone propionate (50 microg/day, sc) plus gavage doses of either corn oil vehicle or fenitrothion (15 or 30 mg/kg/day)." | 1.31 | Androgen receptor antagonism by the organophosphate insecticide fenitrothion. ( Dorman, DC; Gaido, KW; Gray, LE; Maness, SC; Reischmann, K; Tamura, H, 2001) |
| "Eighteen patients with prostate cancer and 17 healthy subjects matched for age and body mass index were included." | 1.31 | Hormonal regulation of appetite and body mass in patients with advanced prostate cancer treated with combined androgen blockade. ( Bryc, W; Kokot, F; Nowicki, M, 2001) |
| "Flutamide was used as a representative potent antiandrogen, and DDE as an example of a weakly active antiandrogen." | 1.31 | Replacement of surgical castration by GnRH-inhibition or Leydig cell ablation in the male rat Hershberger antiandrogen assay. ( Ashby, J; Deghenghi, R; Lefevre, PA; Wallis, N, 2001) |
| " Immature Sprague-Dawley female rats (21 days of age) were dosed daily for 20 days by oral gavage (DES, tamoxifen, and flutamide) or sc injection (testosterone)." | 1.31 | Evaluation of the 20-day pubertal female assay in Sprague-Dawley rats treated with DES, tamoxifen, testosterone, and flutamide. ( Han, SY; Kang, IH; Kim, HS; Kim, IY; Kim, TS; Moon, HJ; Park, KL; Seok, JH; Shin, JH, 2002) |
| " Rats were dosed by the intraperitoneal route for 15 days with vehicle or 0." | 1.30 | Evaluation of the primary humoral immune response following exposure of male rats to 17beta-estradiol or flutamide for 15 days. ( Cook, JC; Ladics, GS; Loveless, SE; Nicastro, SC; O'Connor, JC; Smith, C, 1998) |
| "Flutamide treatment resulted in higher basal levels of testosterone and stress levels of corticosterone compared to vehicle treatment, and there was no interaction of treatment with age at time of treatment." | 1.30 | Persistent effects of prenatal, neonatal, or adult treatment with flutamide on the hypothalamic-pituitary-adrenal stress response of adult male rats. ( Mahoney, E; McCormick, CM, 1999) |
| "Flutamide has also been shown to produce Leydig cell tumors within 1 year, presumably due to sustained hypersecretion of luteinizing hormone (LH) which occurs following disruption of the hypothalamic-pituitary-testicular (HPT) axis." | 1.29 | Investigation of a mechanism for Leydig cell tumorigenesis by linuron in rats. ( Biegel, LB; Cook, JC; Frame, SR; Mullin, LS, 1993) |
| "Cryptorchidism was enhanced when rats were treated postnatally with testosterone or oestradiol." | 1.28 | Disturbed testicular descent in the rat after prenatal exposure to the antiandrogen flutamide. ( van der Schoot, P, 1992) |
| "Flutamide was administered SC at a daily dose of 25 mg/kg." | 1.27 | Investigation of the combination of the agonist D-Trp-6-LH-RH and the antiandrogen flutamide in the treatment of Dunning R-3327H prostate cancer model. ( Redding, TW; Schally, AV, 1985) |
| "Flutamide was used to investigate the mechanism involved in androgen responsive hepatic microsomal drug and steroid metabolism." | 1.27 | Effect of flutamide on hepatic cytosolic methyltrienolone (R1881) binding kinetics and testosterone responsive hepatic drug and steroid metabolism in the adult male rat. ( Bellward, GD; Pak, RC; Sunahara, GI, 1987) |
| "Flutamide treatment decreased the weight of accessory sex organs, stimulated the secretion of both LH (+200%) and FSH (+63%) by inhibition of the negative feedback of testosterone; endogenous testosterone secretion was increased by 363%." | 1.27 | Effects of flutamide or of supplementation with testosterone in prepubertal male rats prenatally treated with busulfan. ( Hochereau-de Reviers, MT; Perreau, C; Viguier-Martinez, MC, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (10.14) | 18.7374 |
| 1990's | 14 (20.29) | 18.2507 |
| 2000's | 33 (47.83) | 29.6817 |
| 2010's | 14 (20.29) | 24.3611 |
| 2020's | 1 (1.45) | 2.80 |
| Authors | Studies |
|---|---|
| Ghasemian, F | 1 |
| Esmaeilnezhad, S | 1 |
| Zacharia, LC | 1 |
| Ryan, GE | 1 |
| Malik, S | 1 |
| Mellon, PL | 1 |
| Pallarés, ME | 1 |
| Adrover, E | 1 |
| Imsen, M | 1 |
| González, D | 1 |
| Fabre, B | 1 |
| Mesch, V | 1 |
| Baier, CJ | 1 |
| Antonelli, MC | 1 |
| Hurliman, A | 1 |
| Keller Brown, J | 1 |
| Maille, N | 1 |
| Mandala, M | 1 |
| Casson, P | 1 |
| Osol, G | 1 |
| da Silva, VA | 1 |
| Dantas, Mde S | 1 |
| Silva, LA | 1 |
| Carneiro, JG | 1 |
| Schamber-Reis, BL | 1 |
| Bhatia, H | 1 |
| Kumar, A | 1 |
| Alonso-Alvarez, C | 1 |
| Pérez-Rodríguez, L | 1 |
| Mateo, R | 1 |
| Chastel, O | 1 |
| Viñuela, J | 1 |
| Moon, HJ | 2 |
| Kang, TS | 2 |
| Kim, TS | 4 |
| Kang, IH | 3 |
| Ki, HY | 1 |
| Kim, SH | 1 |
| Han, SY | 4 |
| Brill, DS | 1 |
| Moenter, SM | 1 |
| Han, Y | 1 |
| Fu, L | 1 |
| Sun, W | 1 |
| Cao, J | 1 |
| Xie, R | 1 |
| Zhou, P | 1 |
| Kang, N | 1 |
| Sun, J | 1 |
| Svensson, AI | 1 |
| Vo, TT | 1 |
| Jung, EM | 1 |
| Dang, VH | 1 |
| Yoo, YM | 1 |
| Choi, KC | 1 |
| Yu, FH | 1 |
| Jeung, EB | 1 |
| Campos, SG | 1 |
| Gonçalves, BF | 1 |
| Scarano, WR | 1 |
| Corradi, LS | 1 |
| Santos, FC | 1 |
| Custodio, AM | 1 |
| Vilamaior, PS | 1 |
| Góes, RM | 1 |
| Taboga, SR | 1 |
| Liew, SH | 1 |
| Drummond, AE | 1 |
| Jones, ME | 1 |
| Findlay, JK | 1 |
| Jung, KK | 1 |
| Kim, SS | 1 |
| Baek, JH | 1 |
| Nam, HS | 1 |
| Hong, SK | 1 |
| Lee, BM | 2 |
| Hong, JT | 1 |
| Oh, KW | 1 |
| Kim, HS | 3 |
| Shimamoto, K | 2 |
| Dewa, Y | 1 |
| Kemmochi, S | 1 |
| Taniai, E | 1 |
| Hayashi, H | 2 |
| Imaoka, M | 1 |
| Shibutani, M | 2 |
| Mitsumori, K | 2 |
| Márquez Hernández, RA | 1 |
| Ohtani, J | 1 |
| Fujita, T | 1 |
| Sunagawa, H | 1 |
| Ishikawa, E | 1 |
| Tsubamoto, N | 1 |
| Kawata, T | 1 |
| Kaku, M | 1 |
| Motokawa, M | 1 |
| Tanne, K | 1 |
| Tawfeeq, MM | 1 |
| Suzuki, K | 2 |
| Inokuma, H | 1 |
| McAllan, BM | 1 |
| Feay, N | 1 |
| Bradley, AJ | 1 |
| Geiser, F | 1 |
| O'Connor, JC | 3 |
| Frame, SR | 3 |
| Ladics, GS | 2 |
| Kwack, SJ | 1 |
| Lee, RD | 1 |
| Kim, IY | 2 |
| Seok, JH | 2 |
| Yoo, SD | 1 |
| Park, KL | 2 |
| Vinggaard, AM | 2 |
| Nellemann, C | 2 |
| Dalgaard, M | 2 |
| Jørgensen, EB | 1 |
| Andersen, HR | 1 |
| Clark, AS | 1 |
| Kelton, MC | 1 |
| Whitney, AC | 1 |
| Baltatu, O | 1 |
| Cayla, C | 1 |
| Iliescu, R | 1 |
| Andreev, D | 1 |
| Bader, M | 1 |
| Nakamura, S | 1 |
| Yamada, T | 2 |
| Hashimoto, T | 1 |
| Takahashi, S | 1 |
| Sogawa, M | 1 |
| Ohara, H | 1 |
| Nakazawa, T | 1 |
| Sano, H | 1 |
| Kuno, A | 1 |
| Joh, T | 1 |
| Nomura, T | 1 |
| Arakawa, T | 1 |
| Itoh, M | 1 |
| Yu, WJ | 1 |
| Nam, SY | 1 |
| Kim, YC | 1 |
| Lee, BJ | 1 |
| Yun, YW | 1 |
| Burns, KH | 1 |
| Agno, JE | 1 |
| Chen, L | 1 |
| Haupt, B | 1 |
| Ogbonna, SC | 1 |
| Korach, KS | 1 |
| Matzuk, MM | 1 |
| Gambineri, A | 1 |
| Pagotto, U | 1 |
| Tschöp, M | 1 |
| Vicennati, V | 1 |
| Manicardi, E | 1 |
| Carcello, A | 1 |
| Cacciari, M | 1 |
| De Iasio, R | 1 |
| Pasquali, R | 1 |
| Lefevre, PA | 2 |
| Ashby, J | 2 |
| Zhang, GJ | 1 |
| Zheng, YF | 1 |
| Zhu, HJ | 1 |
| Zhu, XQ | 1 |
| Smith, MR | 1 |
| Kunimatsu, T | 1 |
| Miyata, K | 1 |
| Yabushita, S | 1 |
| Seki, T | 1 |
| Okuno, Y | 1 |
| Matsuo, M | 1 |
| Nishiyama, T | 1 |
| Ishizaki, F | 1 |
| Anraku, T | 1 |
| Shimura, H | 1 |
| Takahashi, K | 1 |
| Zehr, JL | 1 |
| Van Meter, PE | 1 |
| Wallen, K | 1 |
| Goto, K | 1 |
| Koizumi, K | 1 |
| Takaori, H | 1 |
| Fujii, Y | 1 |
| Furuyama, Y | 1 |
| Saika, O | 1 |
| Suzuki, H | 1 |
| Saito, K | 1 |
| Saruhan, BG | 1 |
| Ozbag, D | 1 |
| Gumusalan, Y | 1 |
| Ozdemir, N | 1 |
| de Zegher, F | 1 |
| Ibáñez, L | 1 |
| Scott, HM | 1 |
| Hutchison, GR | 1 |
| Mahood, IK | 1 |
| Hallmark, N | 1 |
| Welsh, M | 1 |
| De Gendt, K | 1 |
| Verhoeven, G | 1 |
| O'Shaughnessy, P | 1 |
| Sharpe, RM | 1 |
| Metzdorff, SB | 1 |
| Christiansen, S | 1 |
| Axelstad, M | 1 |
| Hass, U | 1 |
| Kiersgaard, MK | 1 |
| Scholze, M | 1 |
| Kortenkamp, A | 1 |
| Tinwell, H | 1 |
| Friry-Santini, C | 1 |
| Rouquié, D | 1 |
| Belluco, S | 1 |
| Elies, L | 1 |
| Pallen, C | 1 |
| Bars, R | 1 |
| Kouvelas, D | 1 |
| Pourzitaki, C | 1 |
| Papazisis, G | 1 |
| Dagklis, T | 1 |
| Dimou, K | 1 |
| Kraus, MM | 1 |
| Nielsen, HC | 1 |
| Zinman, HM | 1 |
| Torday, JS | 1 |
| Brooks, JR | 1 |
| Berman, C | 1 |
| Hichens, M | 1 |
| Primka, RL | 1 |
| Reynolds, GF | 1 |
| Rasmusson, GH | 1 |
| Liu, A | 1 |
| Flores, C | 1 |
| Kinkead, T | 1 |
| Carboni, AA | 1 |
| Menon, M | 1 |
| Seethalakshmi, L | 1 |
| Russo, P | 1 |
| Warner, JA | 1 |
| Huryk, R | 1 |
| Perez, G | 1 |
| Heston, WD | 1 |
| Zimmerberg, B | 1 |
| Farley, MJ | 1 |
| Goulding, A | 1 |
| Gold, E | 1 |
| Cook, JC | 3 |
| Mullin, LS | 1 |
| Biegel, LB | 1 |
| Gallagher, AC | 1 |
| Chambers, TJ | 1 |
| Tobias, JH | 1 |
| Wichmann, MW | 1 |
| Angele, MK | 1 |
| Ayala, A | 1 |
| Cioffi, WG | 1 |
| Chaudry, IH | 1 |
| Smith, C | 1 |
| Nicastro, SC | 1 |
| Loveless, SE | 1 |
| McCormick, CM | 1 |
| Mahoney, E | 1 |
| Kellogg, CK | 1 |
| Lundin, A | 1 |
| Mathias, LJ | 1 |
| Jacobson, NA | 1 |
| Rhees, RW | 1 |
| Lephart, ED | 1 |
| Davis, LG | 1 |
| Tamura, H | 1 |
| Maness, SC | 1 |
| Reischmann, K | 1 |
| Dorman, DC | 1 |
| Gray, LE | 1 |
| Gaido, KW | 1 |
| Kritzer, MF | 1 |
| Pugach, I | 1 |
| Nowicki, M | 1 |
| Bryc, W | 1 |
| Kokot, F | 1 |
| Andrews, P | 1 |
| Freyberger, A | 1 |
| Hartmann, E | 1 |
| Eiben, R | 1 |
| Loof, I | 1 |
| Schmidt, U | 1 |
| Temerowski, M | 1 |
| Becka, M | 1 |
| Deghenghi, R | 1 |
| Wallis, N | 1 |
| Shin, JH | 1 |
| van der Schoot, P | 1 |
| Dhar, JD | 1 |
| Setty, BS | 2 |
| Léger, JG | 1 |
| Le Guellec, R | 1 |
| Tenniswood, MP | 1 |
| Gupta, G | 1 |
| Srivastava, A | 1 |
| Redding, TW | 1 |
| Schally, AV | 1 |
| Sunahara, GI | 1 |
| Pak, RC | 1 |
| Bellward, GD | 1 |
| Viguier-Martinez, MC | 1 |
| Hochereau-de Reviers, MT | 1 |
| Perreau, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Hormonal Regulation of Circulating Endothelial Progenitor Cells and HDL-C in Men Title Changed With New Protocol (12/14/09): Hormonal Regulation of HDL-C in Men[NCT00729859] | Phase 2 | 31 participants (Actual) | Interventional | 2008-12-31 | Completed | ||
| A Pilot Phase IV Study to Evaluate Variation in Bone Mineral Density, Lean and Fat Body Mass Index Measured by Dual-energy X-ray Absorptiometry in Patients With Prostate Cancer Without Bone Metastasis Treated With Degarelix[NCT03202381] | Phase 4 | 35 participants (Anticipated) | Interventional | 2017-06-26 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of CD33 + CD134+ cells as a percentage of all lymphocytes (NCT00729859)
Timeframe: Baseline, Day 28
| Intervention | percentage of all lymphocytes (Mean) | |
|---|---|---|
| Baseline | Day 28 | |
| Group 1: Acyline + Placebo Gel + Placebo Pill | 0.101 | 0.081 |
(NCT00729859)
Timeframe: Baseline, Day 28
| Intervention | pmol/L (Mean) | |
|---|---|---|
| Baseline | Day 28 | |
| Group 1: Acyline + Placebo Gel, Placebo Pill | 95.4 | 31.9 |
| Group 2: Acyline, Testosterone Gel | 117.8 | 109.0 |
| Group 3: Acyline, Testosterone Gel, Anastrozole Pill | 96.3 | 36.5 |
(NCT00729859)
Timeframe: Baseline, Day 28, Day 56
| Intervention | mmol/L (Mean) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total cholesterol Day 0 | Total cholesterol Day 28 | Total cholesterol Day 56 | LDL choesterol Day 0 | LDL cholesterol Day 28 | LDL cholesterol Day 56 | HDL cholesterol Day 0 | HDL cholesterol Day 28 | HDL cholesterol Day 56 | Triglycerides Day 0 | Triglycerides Day 28 | Triglycerides Day 56 | |
| Group 1: Acyline + Placebo Gel, Placebo Pill | 4.97 | 5.44 | 4.95 | 2.95 | 3.29 | 2.87 | 1.19 | 1.37 | 1.19 | 1.79 | 1.73 | 1.89 |
| Group 2: Acyline, Testosterone Gel, Placebo Pill | 4.48 | 4.51 | 4.14 | 2.77 | 2.80 | 2.49 | 1.32 | 1.32 | 1.32 | 0.82 | 0.86 | 0.80 |
| Group 3: Acyline, Testosterone Gel, Oral Anastrozole | 4.56 | 4.56 | 4.27 | 2.67 | 2.75 | 2.51 | 1.40 | 1.32 | 1.30 | 1.08 | 1.08 | 1.02 |
(NCT00729859)
Timeframe: Baseline, Day 28, Day 56
| Intervention | picomolar (Mean) | ||
|---|---|---|---|
| Baseline | Day 28 | Day 56 | |
| Group 1: Acyline + Placebo Gel, Placebo Pill | 54 | 69 | 54 |
| Group 2: Acyline, Testosterone Gel, Placebo Pill | 65 | 59 | 64 |
| Group 3: Acyline, Testosterone Gel, Oral Anastrozole | 50 | 42 | 50 |
(NCT00729859)
Timeframe: Baseline, 28 days
| Intervention | IU/L (Mean) | |
|---|---|---|
| Baseline | Day 28 | |
| Group 1: Acyline + Placebo Gel, Placebo Pill | 4.2 | 0.42 |
| Group 2: Acyline, Testosterone Gel | 2.9 | 0.39 |
| Group 3: Acyline, Testosterone Gel, Anastrazole Pill | 2.5 | 0.87 |
HOMA IR is a measure of insulin sensitivity calculated using fasting insulin and glucose concentration in a participants blood. Higher HOMA IR numbers are associated with increased insulin resistance and decreased insulin sensitivity. (NCT00729859)
Timeframe: Baseline, Day 28, Day 56
| Intervention | HOMA score (Mean) | ||
|---|---|---|---|
| Baseline | Day 28 | Day 56 | |
| Group 1: Acyline + Placebo Gel, Placebo Pill | 1.8 | 2.4 | 2.2 |
| Group 2: Acyline, Testosterone Gel, Placebo Pill | 2.0 | 1.9 | 1.9 |
| Group 3: Acyline, Testosterone Gel, Oral Anastrozole | 1.6 | 1.4 | 1.7 |
(NCT00729859)
Timeframe: Baseline, Day 28
| Intervention | IU/L (Mean) | |
|---|---|---|
| Baseline | Day 28 | |
| Group 1: Acyline + Placebo Gel, Placebo Pill | 4.3 | 0.31 |
| Group 2: Acyline, Testosterone Gel | 4.7 | 0.69 |
| Group 3: Acyline, Testosterone Gel, Anastrozole | 4.4 | 1.55 |
QUICKI is a measure of insulin sensitivity calculated using fasting insulin and glucose concentration in a participants blood. Higher QUICKI are associated with decreased insulin resistance and increased insulin sensitivity. (NCT00729859)
Timeframe: Baseline, Day 28, Day 56
| Intervention | QUICKI index (Mean) | ||
|---|---|---|---|
| Baseline | Day 28 | Day 56 | |
| Group 1: Acyline + Placebo Gel, Placebo Pill | 0.36 | 0.34 | 0.35 |
| Group 2: Acyline, Testosterone Gel, Placebo Pill | 0.35 | 0.35 | 0.35 |
| Group 3: Acyline, Testosterone Gel, Oral Anastrozole | 0.36 | 0.38 | 0.36 |
(NCT00729859)
Timeframe: Baseline, Day 28
| Intervention | nmol/L (Mean) | |
|---|---|---|
| Baseline | Day 28 | |
| Group 1: Acyline + Placebo Gel, Placebo Pill | 34.9 | 37.5 |
| Group 2: Acyline, Testosterone Gel | 23.0 | 22.1 |
| Group 3: Acyline, Testosterone Gel, Anastrozole Pill | 27.6 | 25.1 |
(NCT00729859)
Timeframe: Baseline, Day 28
| Intervention | nmol/L (Mean) | |
|---|---|---|
| Baseline testosterone concentration | Day 28 testosterone concentration | |
| Group 1: Acyline + Placebo Gel, Placebo Pill | 15.4 | 0.8 |
| Group 2: Acyline, Testosterone Gel | 16.3 | 17.8 |
| Group 3: Acyline, Testosterone Gel, Anastrozole | 16.5 | 19.0 |
1 review available for flutamide and Body Weight
| Article | Year |
|---|---|
Permitted Daily Exposure of the Androgen Receptor Antagonist Flutamide.
Topics: Administration, Oral; Androgen Antagonists; Animals; Body Weight; Dose-Response Relationship, Drug; | 2017 |
3 trials available for flutamide and Body Weight
| Article | Year |
|---|---|
Anti-androgen treatment increases circulating ghrelin levels in obese women with polycystic ovary syndrome.
Topics: Adult; Androgen Antagonists; Androstenedione; Blood Glucose; Body Composition; Body Weight; Female; | 2003 |
Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer.
Topics: Adipose Tissue; Adult; Aged; Androgen Antagonists; Body Composition; Body Mass Index; Body Weight; F | 2004 |
Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer.
Topics: Adipose Tissue; Adult; Aged; Androgen Antagonists; Body Composition; Body Mass Index; Body Weight; F | 2004 |
Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer.
Topics: Adipose Tissue; Adult; Aged; Androgen Antagonists; Body Composition; Body Mass Index; Body Weight; F | 2004 |
Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer.
Topics: Adipose Tissue; Adult; Aged; Androgen Antagonists; Body Composition; Body Mass Index; Body Weight; F | 2004 |
The influence of androgen deprivation therapy on metabolism in patients with prostate cancer.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Androgen Antagonists; Blood Glucose; Blood Urea Nit | 2005 |
65 other studies available for flutamide and Body Weight
| Article | Year |
|---|---|
Metformin, clomiphene citrate and flutamide effects on oocyte ultrastructure status and quality in PCOS mouse model.
Topics: Animals; Body Weight; Clomiphene; Female; Fertility Agents, Female; Flutamide; Humans; Infertility, | 2022 |
Antiandrogen Treatment Ameliorates Reproductive and Metabolic Phenotypes in the Letrozole-Induced Mouse Model of PCOS.
Topics: Adipocytes; Androgen Antagonists; Animals; Aromatase Inhibitors; Body Weight; Disease Models, Animal | 2018 |
Maternal administration of flutamide during late gestation affects the brain and reproductive organs development in the rat male offspring.
Topics: Androgen Antagonists; Androgens; Animals; Body Weight; Brain; Female; Flutamide; Hippocampus; Male; | 2014 |
Hyperandrogenism and Insulin Resistance, Not Changes in Body Weight, Mediate the Development of Endothelial Dysfunction in a Female Rat Model of Polycystic Ovary Syndrome (PCOS).
Topics: Androgen Antagonists; Androgens; Animals; Arteries; Blood Pressure; Body Weight; Dihydrotestosterone | 2015 |
Testosterone Depletion Induces Demethylation of Murine Reelin Promoter CpG Dinucleotides: A Preliminary Study.
Topics: Androgen Antagonists; Animals; Body Weight; Brain; Cell Adhesion Molecules, Neuronal; Cerebellum; Cp | 2015 |
Does anti-androgen, flutamide cancel out the in vivo effects of the androgen, dihydrotestosterone on sexual development in juvenile Murray rainbowfish (Melanotaenia fluviatilis)?
Topics: Androgen Antagonists; Androgens; Animals; Body Weight; Dihydrotestosterone; Environmental Exposure; | 2016 |
The oxidation handicap hypothesis and the carotenoid allocation trade-off.
Topics: Androgen Antagonists; Androgens; Animals; Body Weight; Carotenoids; Female; Flutamide; Galliformes; | 2008 |
OECD validation of phase 3 Hershberger assay in Korea using surgically castrated male rats with coded chemicals.
Topics: Anabolic Agents; Androgen Antagonists; Androgens; Animals; Biological Assay; Body Weight; Dichlorodi | 2009 |
Androgen receptor antagonism and an insulin sensitizer block the advancement of vaginal opening by high-fat diet in mice.
Topics: Analysis of Variance; Androgen Antagonists; Animals; Body Weight; Diet, Fat-Restricted; Dietary Fats | 2009 |
Neuroprotective effects of testosterone upon cardiac sympathetic function in rats with induced heart failure.
Topics: Androgen Antagonists; Animals; Blotting, Western; Body Weight; Castration; Flutamide; Gene Expressio | 2009 |
The aromatase inhibitor 1,4,6-androstatriene-3,17-dione (ATD) reduces disinhibitory behavior in intact adult male rats treated with a high dose of testosterone.
Topics: Analysis of Variance; Androgen Antagonists; Androgens; Androstatrienes; Animals; Behavior, Animal; B | 2010 |
Di-(2 ethylhexyl) phthalate and flutamide alter gene expression in the testis of immature male rats.
Topics: Androgen Antagonists; Animals; Body Weight; Diethylhexyl Phthalate; Dose-Response Relationship, Drug | 2009 |
Tissue changes in senescent gerbil prostate after hormone deprivation leads to acquisition of androgen insensitivity.
Topics: Aging; Androgen Antagonists; Androgen-Insensitivity Syndrome; Androgens; Animals; Apoptosis; Body We | 2010 |
The lack of estrogen and excess luteinizing hormone are responsible for the female ArKO mouse phenotype.
Topics: Animals; Aromatase; Body Weight; Corpus Luteum; Estradiol; Estrogens; Estrous Cycle; Female; Flutami | 2010 |
Effects of in utero exposure to DI(n-Butyl) phthalate on development of male reproductive tracts in Sprague-Dawley rats.
Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; Anal Canal; Animals; Body Weight; Cryptorchidism; Dibutyl Pht | 2010 |
Relationship between CYP1A induction by indole-3-carbinol or flutamide and liver tumor-promoting potential in rats.
Topics: Animals; beta-Naphthoflavone; Body Weight; Cytochrome P-450 CYP1A1; Diethylnitrosamine; Enzyme Induc | 2011 |
Mandibular and femoral growth alteration after sex hormone disruption in growing mice.
Topics: Age Factors; Androgen Receptor Antagonists; Animals; Body Weight; Cephalometry; Epiphyses; Estrogen | 2011 |
Mechanistic study on liver tumor promoting effects of flutamide in rats.
Topics: Androgen Antagonists; Animals; Body Weight; Diethylnitrosamine; Flutamide; Immunohistochemistry; Lip | 2012 |
The influence of reproductive hormones on the torpor patterns of the marsupial Sminthopsis macroura: bet-hedging in an unpredictable environment.
Topics: Adaptation, Physiological; Animals; Basal Metabolism; Body Temperature; Body Temperature Regulation; | 2012 |
Evaluation of a 15-day screening assay using intact male rats for identifying antiandrogens.
Topics: Androgen Antagonists; Androgens; Animals; Body Weight; Cyproterone Acetate; Dichlorodiphenyl Dichlor | 2002 |
No androgenic/anti-androgenic effects of bisphenol-A in Hershberger assay using immature castrated rats.
Topics: Androgen Antagonists; Animals; Benzhydryl Compounds; Body Weight; Estrogens, Non-Steroidal; Flutamid | 2002 |
Antiandrogenic effects in vitro and in vivo of the fungicide prochloraz.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Animals; Body Weight; DNA, Complementary; Fluta | 2002 |
Chronic administration of anabolic steroids disrupts pubertal onset and estrous cyclicity in rats.
Topics: Anabolic Agents; Androgen Antagonists; Androgen Receptor Antagonists; Animals; Body Weight; Drug Adm | 2003 |
Abolition of end-organ damage by antiandrogen treatment in female hypertensive transgenic rats.
Topics: Albuminuria; Androgen Antagonists; Animals; Animals, Genetically Modified; Antihypertensive Agents; | 2003 |
Estradiol alleviates acinar cell apoptosis and chronic pancreatitis in male Wistar Bonn/Kobori rats.
Topics: Androgen Antagonists; Animals; Apoptosis; Body Weight; Cell Movement; Chronic Disease; Estradiol; Fl | 2003 |
Effects of tributyltin chloride on the reproductive system in pubertal male rats.
Topics: Animals; Body Weight; Epididymis; Flutamide; Genitalia, Male; Male; Methyltestosterone; Organ Size; | 2003 |
Sexually dimorphic roles of steroid hormone receptor signaling in gonadal tumorigenesis.
Topics: Androgens; Animals; Body Weight; Cachexia; Cyclin D2; Cyclins; Estrogen Receptor alpha; Estrogen Rec | 2003 |
Comparison of prostate gene expression and tissue weight changes as monitors of antiandrogen activity in GNRH-inhibited rats.
Topics: Androgen Antagonists; Androgen-Binding Protein; Animals; Biomarkers; Body Weight; Clusterin; Dichlor | 2003 |
[The antiandrogenic effect of dimethachlon and its mechanism].
Topics: Aminoimidazole Carboxamide; Androgen Antagonists; Androgens; Animals; Body Weight; Bridged Bicyclo C | 2004 |
Evaluation for reliability and feasibility of the draft protocol for the enhanced rat 28-day subacute study (OECD Guideline 407) using androgen antagonist flutamide.
Topics: Androgen Antagonists; Animals; Body Weight; Dose-Response Relationship, Drug; Evaluation Studies as | 2004 |
Factors regulating the timing of puberty onset in female rhesus monkeys (Macaca mulatta): role of prenatal androgens, social rank, and adolescent body weight.
Topics: Age Factors; Androgen Antagonists; Androgens; Animals; Body Weight; Female; Flutamide; Gestational A | 2005 |
Effects of flutamide on sex maturation and behavior of offspring born to female rats treated during late pregnancy.
Topics: Androgen Antagonists; Animals; Animals, Newborn; Body Weight; Cryptorchidism; Dose-Response Relation | 2004 |
Influence of ovariectomy and flutamide treatment on vaginal tissue and body weight.
Topics: Androgen Antagonists; Animals; Body Weight; Disease Models, Animal; Female; Flutamide; Immunohistoch | 2005 |
Prenatal growth restraint followed by catch-up of weight: a hyperinsulinemic pathway to polycystic ovary syndrome.
Topics: Aging; Androgen Antagonists; Body Weight; Child; Drug Therapy, Combination; Female; Fetal Developmen | 2006 |
Role of androgens in fetal testis development and dysgenesis.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Androgen Antagonists; Animals; Body Weight; Carcinogens; Dibutyl P | 2007 |
Dysgenesis and histological changes of genitals and perturbations of gene expression in male rats after in utero exposure to antiandrogen mixtures.
Topics: Algorithms; Androgen Antagonists; Animals; Body Weight; Bridged Bicyclo Compounds; Endpoint Determin | 2007 |
Evaluation of the antiandrogenic effects of flutamide, DDE, and linuron in the weanling rat assay using organ weight, histopathological, and proteomic approaches.
Topics: Adrenal Glands; Androgen Antagonists; Animals; Biomarkers, Pharmacological; Body Weight; Dichlorodip | 2007 |
Nandrolone abuse decreases anxiety and impairs memory in rats via central androgenic receptors.
Topics: Anabolic Agents; Androgen Antagonists; Animals; Anxiety; Behavior, Animal; Body Weight; Brain Chemis | 2008 |
Dihydrotestosterone inhibits fetal rabbit pulmonary surfactant production.
Topics: Animals; Body Weight; Dihydrotestosterone; Dose-Response Relationship, Drug; Female; Flutamide; Huma | 1982 |
Biological activities of a new steroidal inhibitor of delta 4-5 alpha-reductase.
Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; 5-alpha Reductase Inhibitors; Animals; Azasteroids; Body Weig | 1982 |
Effects of sialoadenectomy and epidermal growth factor on testicular function of sexually mature male mice.
Topics: Animals; Body Weight; Epidermal Growth Factor; Flutamide; Follicle Stimulating Hormone; Luteinizing | 1994 |
TRPM-2 gene expression in normal rat ventral prostate following castration and exposure to diethylstilbestrol, flutamide, MK-906 (finasteride), and coumarin.
Topics: Animals; Apoptosis; Body Weight; Clusterin; Coumarins; Diethylstilbestrol; Finasteride; Flutamide; G | 1994 |
Sex differences in anxiety behavior in rats: role of gonadal hormones.
Topics: Animals; Animals, Newborn; Anxiety; Appetitive Behavior; Arousal; Body Weight; Conditioning, Operant | 1993 |
Flutamide-mediated androgen blockade evokes osteopenia in the female rat.
Topics: Androgens; Animals; Body Weight; Bone Density; Bone Diseases, Metabolic; Buserelin; Female; Flutamid | 1993 |
Investigation of a mechanism for Leydig cell tumorigenesis by linuron in rats.
Topics: Age Factors; Androgen Antagonists; Animals; Binding, Competitive; Body Weight; Cell Transformation, | 1993 |
Androgens contribute to the stimulation of cancellous bone formation by ovarian hormones in female rats.
Topics: Animals; Body Weight; Bone and Bones; Bone Resorption; Dihydrotestosterone; Diphosphonates; Female; | 1996 |
Flutamide: a novel agent for restoring the depressed cell-mediated immunity following soft-tissue trauma and hemorrhagic shock.
Topics: Animals; Body Weight; Corticosterone; Flutamide; Immunity, Cellular; Injections, Subcutaneous; Inter | 1997 |
Evaluation of the primary humoral immune response following exposure of male rats to 17beta-estradiol or flutamide for 15 days.
Topics: Androgen Antagonists; Animals; Body Weight; Cell Count; Environmental Pollutants; Estradiol; Flutami | 1998 |
Persistent effects of prenatal, neonatal, or adult treatment with flutamide on the hypothalamic-pituitary-adrenal stress response of adult male rats.
Topics: Age Factors; Anal Canal; Androgen Antagonists; Animals; Animals, Newborn; Body Weight; Corticosteron | 1999 |
Brain androgen-inducible aromatase is critical for adolescent organization of environment-specific social interaction in male rats.
Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; 5-alpha Reductase Inhibitors; Adaptation, Physiological; Adap | 1999 |
Brain aromatase in control versus castrated Norway Brown, Sprague-Dawley and Wistar adult rats.
Topics: Amygdala; Androgen Antagonists; Animals; Aromatase; Body Weight; Brain; Castration; Flutamide; Hypot | 1999 |
Detection of the environmental antiandrogen p,p-DDE in CD and long-evans rats using a tier I screening battery and a Hershberger assay.
Topics: Animals; Body Weight; Dichlorodiphenyl Dichloroethylene; Disease Models, Animal; Flutamide; Gonadal | 1999 |
Androgen receptor antagonism by the organophosphate insecticide fenitrothion.
Topics: Acetylcholinesterase; Androgen Receptor Antagonists; Animals; Body Weight; Carcinoma, Hepatocellular | 2001 |
Administration of tamoxifen but not flutamide to hormonally intact, adult male rats mimics the effects of short-term gonadectomy on the catecholamine innervation of the cerebral cortex.
Topics: Animals; Axons; Body Weight; Cerebral Cortex; Dopamine; Dopamine beta-Hydroxylase; Flutamide; Male; | 2001 |
Hormonal regulation of appetite and body mass in patients with advanced prostate cancer treated with combined androgen blockade.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Appetite | 2001 |
Feasibility and potential gains of enhancing the subacute rat study protocol (OECD test guideline no. 407) by additional parameters selected to determine endocrine modulation. A pre-validation study to determine endocrine-mediated effects of the antiandro
Topics: Administration, Oral; Androgen Antagonists; Animals; Behavior, Animal; Body Weight; Clinical Chemist | 2001 |
Replacement of surgical castration by GnRH-inhibition or Leydig cell ablation in the male rat Hershberger antiandrogen assay.
Topics: 5-alpha Reductase Inhibitors; Androgen Antagonists; Animals; Body Weight; Dichlorodiphenyl Dichloroe | 2001 |
Evaluation of the 20-day pubertal female assay in Sprague-Dawley rats treated with DES, tamoxifen, testosterone, and flutamide.
Topics: Administration, Oral; Animals; Body Weight; Diethylstilbestrol; Dose-Response Relationship, Drug; Es | 2002 |
Disturbed testicular descent in the rat after prenatal exposure to the antiandrogen flutamide.
Topics: Androgen-Insensitivity Syndrome; Animals; Body Weight; Chi-Square Distribution; Cryptorchidism; Epid | 1992 |
Effect of a nonsteroidal antiandrogen, anandron, on the reproductive system and fertility in male rats.
Topics: Alkaline Phosphatase; Androgen Antagonists; Animals; Body Weight; Dose-Response Relationship, Drug; | 1990 |
Treatment with antiandrogens induces an androgen-repressed gene in the rat ventral prostate.
Topics: Androgen Antagonists; Androgens; Animals; Blotting, Northern; Body Weight; Cell Survival; Cell-Free | 1988 |
Effect of antiandrogens on some key enzymes of glycolysis in epididymis and ventral prostate of rat.
Topics: Androgen Antagonists; Animals; Body Weight; Cyproterone; Cyproterone Acetate; Enzymes; Epididymis; E | 1989 |
Investigation of the combination of the agonist D-Trp-6-LH-RH and the antiandrogen flutamide in the treatment of Dunning R-3327H prostate cancer model.
Topics: Anilides; Animals; Body Weight; Cell Line; Drug Therapy, Combination; Flutamide; Gonadotropin-Releas | 1985 |
Effect of flutamide on hepatic cytosolic methyltrienolone (R1881) binding kinetics and testosterone responsive hepatic drug and steroid metabolism in the adult male rat.
Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; Androgen-Binding Protein; Anilides; Animals; Aryl Hydrocarbon | 1987 |
Effects of flutamide or of supplementation with testosterone in prepubertal male rats prenatally treated with busulfan.
Topics: Anilides; Animals; Body Weight; Busulfan; Female; Flutamide; Follicle Stimulating Hormone; Hypothala | 1985 |